Share on StockTwits
 

Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Monday, American Banking and Market News reports. The firm currently has a $5.40 price target on the stock. Zacks‘ target price would suggest a potential upside of 12.27% from the stock’s previous close.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up 0.84% during mid-day trading on Monday, hitting $4.81. The stock had a trading volume of 233,364 shares. Sunesis Pharmaceuticals has a one year low of $4.26 and a one year high of $6.54. The stock has a 50-day moving average of $4.75 and a 200-day moving average of $4.97. The company’s market cap is $259.7 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.20) by $0.04. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.44 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was up 640.7% on a year-over-year basis. Analysts expect that Sunesis Pharmaceuticals will post $-0.72 EPS for the current fiscal year.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.